Real-World Effectiveness of Nirmatrelvir/Ritonavir in Preventing Hospitalization Among Patients With COVID-19 at High Risk for Severe Disease in the United States: A Nationwide Population-Based Cohort Study

Xiaofeng Zhou, Scott P. Kelly, Caihua Liang, Ling Li, Rongjun Shen, Heidi K. Leister-Tebbe, Steven G. Terra, Michael Gaffney, Leo Russo
doi: https://doi.org/10.1101/2022.09.13.22279908

Article usage

Article usage: September 2022 to August 2025

AbstractFullPdf
Sep 2022161014329
Oct 20225004142
Nov 20223501082
Dec 20224386127
Jan 20232625120
Feb 20232011076
Mar 2023205976
Apr 2023117242
May 2023107435
Jun 2023133422
Jul 202378121
Aug 2023731031
Sep 2023132523
Oct 202393422
Nov 2023821217
Dec 202363428
Jan 202484418
Feb 202458517
Mar 202437523
Apr 202444718
May 202464425
Jun 202448028
Jul 202456431
Aug 202453236
Sep 202453619
Oct 202463618
Nov 202456318
Dec 202439020
Jan 202534120
Feb 2025411611
Mar 2025704433
Apr 2025551224
May 2025491724
Jun 2025481819
Jul 2025512234
Aug 2025230
Back to top
Posted September 14, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Real-World Effectiveness of Nirmatrelvir/Ritonavir in Preventing Hospitalization Among Patients With COVID-19 at High Risk for Severe Disease in the United States: A Nationwide Population-Based Cohort Study
Xiaofeng Zhou, Scott P. Kelly, Caihua Liang, Ling Li, Rongjun Shen, Heidi K. Leister-Tebbe, Steven G. Terra, Michael Gaffney, Leo Russo
medRxiv 2022.09.13.22279908; doi: https://doi.org/10.1101/2022.09.13.22279908
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area